Pancreatic Neuroendocrine Tumor
📧 Sign up to get email alerts when something new happens for Pancreatic Neuroendocrine Tumor.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-03-23Clinical Trial Update: Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases [Phase 2]
Phase 2 clinical trial evaluated isolated hepatic perfusion with melphalan for patients with primary unresectable liver cancer or liver meta…
-
CLINICAL_TRIALS trial_result · 2011-12-15Clinical Trial Update: Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors [Phase 3]
Phase 3 trial comparing Everolimus to placebo in patients with advanced pancreatic neuroendocrine tumors reports efficacy and safety results…
-
CLINICAL_TRIALS trial_result · 2011-03-22Clinical Trial Update: Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors [Phase 2]
Phase 2 trial of Avastin (bevacizumab) with fluorouracil, doxorubicin, and streptozocin in locally advanced and metastatic pancreatic neuroe…
-
CLINICAL_TRIALS trial_result · 2010-12-07Clinical Trial Update: RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma [Phase 2]
A Phase 2 trial evaluating everolimus (RAD001) in combination with octreotide depot in metastatic or unresectable low-grade neuroendocrine t…
-
CLINICAL_TRIALS trial_result · 2010-10-11Clinical Trial Update: A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors [Phase 3]
A Phase 3 trial comparing sunitinib to placebo for advanced pancreatic islet cell tumors was terminated. Results were posted in October 2010…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2009-10-07Clinical Trial Update: High Dose Somatostatin Analogues in Neuroendocrine Tumors [Phase 2]
A Phase 2 trial evaluating high-dose somatostatin analogues in neuroendocrine tumors has completed.
-
FDA approval · 2009-03-03FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for octreotide acetate submitted by Hikma Pharmaceuticals USA Inc., under the ANDA pathway.